Chronos Archive seal

Review checklist: Georgia O'Keeffe (HR-ET011)

All records · Back to the record · Dossier (sources.md) · Terminology · Report a problem · Comments

Everything a reviewer needs to judge, gathered from the record. Release status: draft.

Review status

ReviewStatusReviewerDateNotes
schema validationnot_startedRun scripts/build.ps1 -Conformance.
clinical reviewnot_startedAwaiting clinician review.
provenance reviewnot_startedO'Keeffe Museum chronology and biography, Whitney Museum text, and the Vision & Art Project logged; the 1972 letter and the 1992 biography were not reviewed directly.
safe messaging reviewnot_startedThe 1933 hospitalization is recorded as history in the period's term and marked sensitive; no modern psychiatric diagnosis is inferred. Death recorded without graphic detail.

Judgment calls (dossier editorial resolutions)

  1. Index age. The modern episode presents O’Keeffe at 80, her age in 1968, when the museum chronology records that her eyesight began to fail. The synthetic date of birth is November 15, 1945 (shift 58 years), so the chronic-care visits from March to July 2026 map to March to July 1968; the sick and wellness visits are described below. Past medical history and family history include only events before the index date; the 1971 loss of central vision, her later work with assistants, and her death remain in the historical timeline.
  2. Type of macular degeneration. The sources say macular degeneration but not whether it was dry or neovascular. The modern episode makes the left eye neovascular and the right eye intermediate dry AMD, consistent with the 1972 letter describing the left eye as worse. Both are synthetic.
  3. Teaching contrast. Her documented course, from failing sight in 1968 to central vision loss in 1971, happened before anti-VEGF therapy existed. The synthetic episode shows what modern treatment and monitoring would offer; it does not claim that treatment would have changed her course.
  4. 1933 hospitalization. The museum chronology records “psychoneurosis.” The term is kept as recorded and marked sensitive; no modern psychiatric diagnosis is inferred or coded, so no safety assessment is required.
  5. Earlier onset. The suggestion that first signs appeared as early as 1964 comes from a secondary advocacy source and is graded R, possible. It is kept off the problem list.
  6. Sick and wellness visits. Two visits were added after the chronic-care schedule: an unscheduled sick visit on August 20, 2026 (true frame August 20, 1968) for a left ankle sprain after a fall, and a subsequent annual wellness visit on October 15, 2026 (true frame October 15, 1968). Both are synthetic, and the fall does not echo a documented injury. A trip on an unseen edge in low-contrast light was chosen because reduced contrast sensitivity from macular degeneration is a recognized cause of falls, and it lets the wellness visit teach fall, home-safety, and driving review for an older adult with low vision who lives alone. The wellness visit uses the acuity recorded at the July retina visit rather than inventing a new measurement, and does not describe retina visits after July. Immunizations follow her synthetic record: the second zoster dose is given late without restarting the series, and pneumococcal, RSV, and tetanus vaccines are listed as due because none is on record. Its advance care planning names no real person as her health care agent.
  7. Medications. Intravitreal aflibercept is recorded as procedures, because the schema has no intravitreal route. The AREDS2 supplement is recorded as an intervention, because RxNorm has no single clinical drug for the full AREDS2 formula. The medication list is therefore empty.
  8. Not used. Biographies’ accounts of her relationships, the 1978 lawsuit, and secondhand reports that her vision loss was kept quiet were not needed for the clinical teaching and are not recorded. Causes of her parents’ deaths were not given in the cited source.
  9. Focused visits. The four retina follow-ups (the March consultation with the first injection, the second and third loading injections, and the first treat-and-extend visit in July) are documented as focused visits on the AAO macular degeneration Preferred Practice Pattern, with the CMID cataract and glaucoma eye-examination items and general depression and cognitive items. Each lists every item the protocol calls for at that point, with its interval and status. Synthetic findings introduced: the fundus descriptions, a small subconjunctival hemorrhage after the first injection that resolved, the post-injection optic nerve perfusion checks, and the timing of the low-vision rehabilitation steps (referral at the consultation, evaluation in May, completion with a daytime local driving clearance by July), which agree with the goal outcomes and the later wellness visit. Protocol deviations recorded instead of invented results: no fluorescein or OCT angiography at diagnosis (treatment began on OCT alone; the response to loading supports the diagnosis), and the post-injection pressure check was made by optic nerve perfusion rather than a second pressure reading.
  10. Consultation. The retina referral and consultation are synthetic and written for this case. Dr. Tanabe's examination repeats the focused note of the consultation day, and her recommendations agree with what followed: three monthly aflibercept loading doses and then treat-and-extend; the AREDS2 supplement and daily Amsler checks started that day; fluorescein or OCT angiography held in reserve for a poor or atypical response, and not needed because the response to loading was typical; and the low-vision referral with a home fall-risk review and driving assessment, which later cleared her for short local daytime driving. Judgment calls: until that assessment the consultant limits her to short local daytime routes, on the strength of the right-eye acuity; and the after-injection check is recorded as optic nerve perfusion and counting fingers, matching the recorded deviation, not as a second pressure reading.
  11. Presenting concern. The intake documents list the presenting concern (PRB-004) rather than the macular degeneration in both eyes, which is recorded from the retina consultation, where OCT made the diagnosis. The presenting-concern problem is synthetic (S); it is resolved, superseded by the diagnosis, from that visit on.
  12. O’Keeffe died in 1986, so the recent-death review rule does not apply. Ordinary clinical, provenance, and safe-messaging reviews remain required.

Protocol deviations

Checks the monitoring protocol called for that the schedule did not perform. Each is recorded with its outcome and corrective action, never filled with an invented result.

VisitMeasureIntervalWhat happened
2026-03-12
Progress note 02 (C-CDA)
Fluorescein angiography or OCT angiographyAt diagnosis of suspected neovascular AMDNot performed. OCT and fundus findings were typical, so treatment began the same day without angiography, a departure from the PPP's diagnostic recommendation. Angiography will be done if the response to loading is poor or the picture becomes atypical

Orders and referrals without results in the record

VisitTypeItemStatusDetail
2026-03-12
Progress note 02 (C-CDA)
ReferralLow-vision rehabilitation, with home fall-risk review and a driving assessmentReferredReferral sent today
2026-04-09
Progress note 03 (C-CDA)
ReferralLow-vision rehabilitation, with home fall-risk review and a driving assessmentReferredEvaluation booked for next month
2026-05-07
Progress note 04 (C-CDA)
ReferralLow-vision rehabilitation, with home fall-risk review and a driving assessmentReferredEvaluation done this month; home visit and driving assessment under way
2026-10-15
Progress note 07 (C-CDA)
PreventionBone density (DXA)OrderedNo prior scan on record; recommended for women 65 and older, and her fall with injury and low body weight raise the stakes of a fracture
2026-10-15
Progress note 07 (C-CDA)
PreventionFalls preventionReferredFall with injury this year; Timed Up and Go 11 seconds; physical therapy referral for balance and strength exercise and written home-safety changes
2026-10-15
Progress note 07 (C-CDA)
PreventionCholesterol and diabetes screeningOrderedNo lipid panel or glucose on record; ordered with the next blood draw. Any statin decision at her age would be shared

Evidence to check

Retrospective claims (R)

ClaimStatementCertainty
CLM-0010The first signs of O'Keeffe's macular degeneration may have appeared as early as 1964.possible

Sensitive claims

ClaimGradeStatement
CLM-0005DIn February 1933 O'Keeffe was admitted to Doctor's Hospital in New York, suffering from psychoneurosis, and recuperated in Bermuda in March and April.

Diagnoses not confirmed

None.

Notes to read

Every note in the record, with its type. All clinical content is synthetic.

Abnormal results

DateResultValueFlag
2026-03-10Best-corrected visual acuity, right eye (ETDRS letters)78 (low)Low
2026-03-10Best-corrected visual acuity, left eye (ETDRS letters)56 (low)Low
2026-03-12Best-corrected visual acuity, right eye (ETDRS letters)78 (low)Low
2026-03-12Best-corrected visual acuity, left eye (ETDRS letters)55 (low)Low
2026-03-12Central subfield thickness by OCT, left eye418 um (high)High
2026-04-09Best-corrected visual acuity, left eye (ETDRS letters)64 (low)Low
2026-04-09Central subfield thickness by OCT, left eye322 um (high)High
2026-05-07Best-corrected visual acuity, left eye (ETDRS letters)69 (low)Low
2026-07-02Best-corrected visual acuity, right eye (ETDRS letters)77 (low)Low
2026-07-02Best-corrected visual acuity, left eye (ETDRS letters)70 (low)Low